Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;54(1):775-789.
doi: 10.1080/07853890.2021.1993327.

Impact of colchicine on mortality and morbidity in COVID-19: a systematic review

Devang Sanghavi  1 , Pankaj Bansal  2 , Ikwinder Preet Kaur  3 , Mohsin Sheraz Mughal  3 , Chandana Keshavamurthy  4 , Austin Cusick  5 , Jennifer Schram  6 , Siva Naga S Yarrarapu  7 , Abhishek R Giri  1 , Nirmaljot Kaur  8 , Pablo Moreno Franco  1 , Andy Abril  9 , Fawad Aslam  10
Affiliations

Impact of colchicine on mortality and morbidity in COVID-19: a systematic review

Devang Sanghavi et al. Ann Med. 2022 Dec.

Abstract

Introduction: Colchicine, because of its anti-inflammatory and possible anti-viral properties, has been proposed as potential therapeutic option for COVID-19. The role of colchicine to mitigate "cytokine storm" and to decrease the severity and mortality associated with COVID-19 has been evaluated in many studies.

Objective: To evaluate the role of colchicine on morbidity and mortality in COVID-19 patients.

Methods: This systematic review was conducted in accordance with the PRISMA recommendations. The literature search was conducted in 6 medical databases from inception to February 17, 2021 to identify studies evaluating colchicine as a therapeutic agent in COVID-19. All included studies were evaluated for risk of bias (ROB) using the Revised Cochrane ROB tool for randomised controlled trials (RCTs) and Newcastle-Ottawa Scale (NOS) for case-control and cohort studies.

Results: Four RCTs and four observational studies were included in the final analysis. One study evaluated colchicine in outpatients, while all others evaluated inpatient use of colchicine. There was significant variability in treatment protocols for colchicine and standard of care in all studies. A statistically significant decrease in all-cause mortality was observed in three observational studies. The risk of mechanical ventilation was significantly reduced only in one observational study. Length of hospitalisation was significantly reduced in two RCTs. Risk for hospitalisation was not significantly decreased in the study evaluating colchicine in outpatients. Very few studies had low risk of bias.

Conclusion: Based on the available data, colchicine shall not be recommended to treat COVID-19. Further high-quality and multi-center RCTs are required to assess the meaningful impact of this drug in COVID-19.KEY MESSAGESColchicine, an anti-inflammatory agent has demonstrated anti-viral properties in in-vitro studies by degrading the microtubules, as well as by inhibiting the production of pro-inflammatory cytokines.Colchicine has been studied as a potential therapeutic option for COVID-19, with variable results.Until further research can establish the efficacy of colchicine in COVID-19, the use of colchicine in COVID-19 shall be restricted to clinical trials.

Keywords: COVID-19; Colchicine; Coronavirus.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. WHO coronavirus (COVID-19) dashboard [Internet] . [cited 2021. Sep 1]. Available from: https://covid19.who.int.
    1. Kelleni MT. Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment. SN Compr Clin Med. 2021;3(4):919–923. - PMC - PubMed
    1. Ivan Hariyanto T, Kurniawan A.. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. J Med Virol. 2021;93(3):1832–1836. - PMC - PubMed
    1. Hariyanto TI, Halim DA, Rosalind J, et al. . Ivermectin and outcomes from covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies. Rev Med Virol. 2021.
    1. Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, et al. . COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Front Med. 2021;8:644295. - PMC - PubMed

Publication types